Verition Fund Management
SPRY icon

Verition Fund Management’s ARS Pharmaceuticals SPRY Stock Holding History

Verition Fund Management’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-27,681
Closed -$348K – 3848
2025
Q1 		$348K Buy
27,681
+12,243
+79% +$147K ﹤0.01% 2788
2024
Q4 		$163K Buy
15,438
+4,975
+48% +$69.7K ﹤0.01% 3019
2024
Q3 		$152K Sell
10,463
-16,462
-61% -$196K ﹤0.01% 2940
2024
Q2 		$229K Buy
+26,925
New +$239K ﹤0.01% 2510
2023
Q2 		– Sell
-23,869
Closed -$155K – 2522
2023
Q1 		$155K Buy
+23,869
New +$183K ﹤0.01% 1831

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Verition Fund Management's SPRY Position: Q2 2025 in Review

Verition Fund Management sold out of ARS Pharmaceuticals (SPRY) in Q2 2025, closing a stake of 27,681 shares — an estimated $348K sold.

Verition Fund Management first reported a position in SPRY in Q1 2023 and held it in 5 quarters. The position peaked at $348K in Q1 2025. 187 funds tracked by Wall St. Rank hold SPRY as of Q2 2025.

  • Verition Fund Management reported no remaining ARS Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Verition Fund Management sold 27,681 ARS Pharmaceuticals shares in Q2 2025, an estimated $348K.
  • Verition Fund Management first reported a position in ARS Pharmaceuticals in Q1 2023 and held it in 5 quarters.
  • Verition Fund Management's ARS Pharmaceuticals position peaked at $348K in Q1 2025.
  • 187 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2025.

Based on Verition Fund Management's 13F filing for Q2 2025, filed 14 Aug 2025.